Trading Ideas On The Upcoming CTAD 2022 Conference

Nov. 02, 2022 3:27 PM ETABOS, ATHA, AVXL, BIIB, BIVI, LLY, NGENF, PRTA, RHHBF, RHHBY, SAVA, ESALY21 Comments
E. Roudasev profile picture
E. Roudasev
1.33K Followers

Summary

  • The Clinical Trials on Alzheimer’s Conference will take place from November 29, 2022 to December 2, 2022.
  • Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.
  • This conference will in any case be one to remember for the Eisai data alone, but I expect more interesting data may be published.
  • I am giving my thoughts on possibly actionable ideas.

Trading charts background

da-kuk

Introduction

Alzheimer’s conferences have in the past, more than once, shown to be either catalysts or exactly the opposite for companies’ stocks. With the amyloid-targeting field being hot again, and by a larger extent the Alzheimer’s field, I am setting out my thoughts on the upcoming

This article was written by

E. Roudasev profile picture
1.33K Followers
I am working in the financial sector. My areas of interest are technology, biotech, pharmaceutical companies, banks and a bit of shipping when an actionable trade passes on my radar.

Disclosure: I/we have a beneficial long position in the shares of AVXL, BIVI, ATHA, INMB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I have no short positions on any of the mentioned stocks, and do not intend to take any such positions in the near future.

Recommended For You

Comments (21)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.